Release MSS5

Rilasciare MSS5, App per studio clinico.

Release MSS5 Clinical Study App. contains content that is new and is tailored for the phase 3 study of Nabiximols Oromucosal Spray entitled:

A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis.

The clinical study app. enables study participants to complete daily eDiary entries and view scheduled study appointments during study participation.

GWSP20105 – Study Participant App. The App does not provide medical advice. Please consult with your study doctor with any questions or concerns you may have regarding your individual needs or medical conditions or any related questions about your involvement in the study.